Parkinson’s Disease Treatment Market Size, Share & Trends Analysis Report By Drug Class (Carbidopa-levodopa, Anticholinergics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global Parkinson’s disease treatment market size was valued at USD 4.28 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2022 to 2030. The increasing geriatric population, which is exposed to a high risk of developing Parkinson’s Disease (PD), the high burden of PD in western countries, and the strong product pipeline of disease-modifying therapies are anticipated to be major drivers for the industry. According to the International Parkinson and Movement Disorder Society, in 2020, around 9.4 million individuals had PD worldwide. Moreover, PD affects around 1% of the total population over the age of 60 years, which rises to 5% for the population over the age of 85 years.

Moreover, according to a UN report, there were about 727 million people aged 65 years & above globally in 2020. In addition, the number of individuals aged 80 years and above is projected to double by 2050, reaching more than 1.5 billion globally. Hence, the rise in the prevalence of PD has paved the way for key pharmaceutical players to undertake extensive market growth in this sector. The availability of different dosage forms can enable product differentiation for pharmaceutical companies, resulting in greater profits. NeuroDerm is developing ND0612 for the treatment of patients with moderate-to-severe PD, for whom oral medications are no longer effective.

In addition, LY03003 (Rotigotine ER Microsphere) and P2B001 (extended-release (ER) formulations of pramipexole and rasagiline) are currently being developed by Luye Pharma Group and Pharma Two B respectively. Chronic PD requires treatment for a long duration, along with critical care. Treatments of such illnesses require high expenditure. The treatment cost for PD varies depending on the region. According to a research study, the direct annual medical cost per PD patient is estimated to be around USD 10,043 to USD 12,491 in the U.S.; out of this, prescription drugs accounted for around 14-22%. Owing to favorable healthcare policies and reimbursement scenarios in developed countries such as the U.S., the overall cost burden on an individual patient is reduced.

Drug Class Insights

The Carbidopa-levodopa drug class segment dominated the industry with a revenue share of more than 25.00% in 2021. This growth was attributed to the high prescription rate of these drugs. According to the U.S. Drug Use Statistics, the estimated number of Carbidopa-Levodopa prescriptions was found to be 527,530 for 183,690 Parkinson’s patients in 2020. Carbidopa and Levodopa are a combination of medicines indicated to treat symptoms of PD. It is the most potent and highly used medication for PD as a second line of treatment. It is primarily available in the oral route of administration, such as in the form of immediate-release tablets, controlled-release tablets, enteral suspension, and extended-release capsules.

Furthermore, the presence of pipeline candidates such as LY03003, coupled with a rise in the demand for dopamine agonists, are factors expected to positively contribute to segment growth. According to the American PD Association (APDA), currently, there are four FDA-approved Dopamine Agonists, which include Requip (ropinirole), Mirapex (pramipexole), Apokyn (apomorphine), and Neupro (rotigotine), available in the U.S. to treat patients suffering from PD. Ropinirole and Pramipexol are available in both long-acting and regular formulations. Apomorphine is delivered by intravenous injection and is considered rescue medication within 10 minutes. Therefore, the approval of novel medicines for the treatment of the disease will also drive segment growth.

Distribution Channel Insights

The retail pharmacy segment dominated the global industry in 2021 and accounted for the largest share of 59.10% of the overall revenue. The segment is anticipated to expand further at the fastest growth rate during the forecast period. According to Parkinson’s news today, PD affects around 41 individuals per 100,000 in their 40s, to more than 1,900 people per 100,000 in their 80s and 90s. It is the second-most common neurodegenerative disorder after Alzheimer’s disease. Currently, PD is not completely curable and it takes lifelong support of medications. The majority of this medication consumption is associated with retail pharmacies. All these factors are expected to propel the segment growth during the projection period.

Furthermore, the ease of availability of PD drugs including generic carbidopa-levodopa, pramipexole dihydrochloride, selegiline hydrochloride, and others in retail pharmacy chains, such as Walgreens and Walmart Stores, boosts the segment growth. The online pharmacy segment is expected to witness a significant growth rate during the forecast period. The trend of online shopping is growing due to the comfort, flexibility, and convenience offered by these platforms. This, in turn, is generating high revenues, thereby driving the growth of the online segment. Moreover, online shopping offers various discounts, benefiting customers. This factor is expected to boost the demand for online pharmacies during the forecast period.

Regional Insights

North America dominated the global industry with a maximum revenue share of 37.90% in 2021. This dominance can be attributed to the presence of leading players in the region, such as AbbVie Inc., Merck & Co. Inc., Amneal Pharmaceuticals LLC., and Sunovion Pharmaceuticals Inc. These players support growth by introducing new PD symptom management products. For instance, in May 2020, the U.S. FDA approved Kynmobi developed by Sunovion Pharmaceuticals Inc., to treat off-episodes in patients with PD. Furthermore, extensive research in the field of PD in the region is anticipated to positively contribute to the market growth.

For instance, in Canada, in January 2022, BlueRock Therapeutics administered the first dose of DA01 (dopaminergic neurons) in patients with advanced PD. Successful completion of the trial and subsequent approval of the product is anticipated to drive the region’s growth during the forecast period. Asia Pacific is estimated to register the fastest growth rate during the assessment period. This is due to the increased product penetration, untapped potential, and growing prevalence of PD in developing countries. For instance, in July 2022, UCB S.A. received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) for the supply and delivery of Neupro in China. Neupro is recommended as a monotherapy in combination with levodopa to treat patients with early-stage idiopathic PD.

Key Companies & Market Share Insights

Major players are adopting strategies, such as mergers & acquisitions, and collaborations, for regional expansion and for a greater market share. In June 2022, Biogen Inc. and Alectos Therapeutics collaborated to sign an agreement to develop and commercialize GBA2 inhibitors (AL01811), a potential treatment for patients suffering from PD. This agreement gives rights to Biogen for the development, manufacturing, and commercialization of AL01811 worldwide. Some of the prominent players in the global Parkinson’s disease treatment market include:

• Cerevel Therapeutics

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

• Merck & Co., Inc.

• GlaxoSmithKline plc. (GSK)

• AbbVie, Inc.

• H. Lundbeck A/S

• Amneal Pharmaceuticals LLC

• Supernus Pharmaceuticals, Inc.

Parkinson’s Disease Treatment Market Report Scope

Global Parkinson’s Disease Treatment Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global Parkinson’s disease treatment market report on the basis of drug class, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Carbidopa-levodopa

  • Dopamine Agonists

  • MAO-B Inhibitors

  • COMT inhibitors

  • Anticholinergics

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • Spain

    • France

    • Italy

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE